Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Product review on the IMD serogroup B vaccine Bexsero®

31 Jan 2022

Abstract excerpt

: the fHbp, NHBA, NadA and PorA. This vaccine was licensed against invasive meningococcal disease (IMD) due to serogroup B isolates. When administered alone, Bexsero® showed a safety profile similar to other childhood vaccines. It provides an excellent immunogenicity but that requires booster doses in infants and young children. Although the vaccine does not seem to impact on acquisition of carriage of serogroup...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumocystis jirovecii pneumonia detection and treatment
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35192786
DOI: 10.1080/21645515.2021.2020043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Product review on the IMD serogroup B vaccine Bexsero®PMID 35192786Read ↗

BexseroSemantic proximity Read ↗

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineSemantic proximity Read ↗

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in ItalySemantic proximity Read ↗

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern SpainSemantic proximity Read ↗

<i>Neisseria meningitidis</i>B vaccines: recent advances and possible immunization policiesSemantic proximity Read ↗

<i>Neisseria meningitidis</i>serogroup B bivalent factor H binding protein vaccineSemantic proximity Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineSemantic proximity Read ↗

Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisationSemantic proximity Read ↗

Bexsero® chronicleSemantic proximity Read ↗

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.Semantic proximity Read ↗

Review of Meningococcal Group B VaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.